Literature DB >> 32588960

Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic.

Yang-Yang Ding1, Sneha Ramakrishna2, Adrienne H Long2, Charles A Phillips1, Raul Montiel-Esparza2, Caroline J Diorio1, L Charles Bailey1, Shannon L Maude1, Richard Aplenc1, Vandana Batra1, Anne F Reilly1, Susan R Rheingold1, Norman J Lacayo2, Kathleen M Sakamoto2, Stephen P Hunger1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32588960      PMCID: PMC7361231          DOI: 10.1002/pbc.28427

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.838


× No keyword cloud information.
To the Editor, Although the effects of the SARS‐CoV‐2 virus on infected patients are increasingly documented, the indirect consequences for uninfected patients are less well described. We report five cases of children who presented critically ill to two U.S. tertiary referral centers (Children's Hospital of Philadelphia [CHOP] and Lucile Packard Children's Hospital at Stanford [LPCH]) in April 2020. All patients tested SARS‐CoV‐2 negative and experienced delays in cancer diagnosis due to the COVID‐19 pandemic with grave consequences. Each patient required emergent life‐saving interventions shortly after presentation (Table 1), including resuscitation following cardiac arrest (N = 2), emergent intubation (N = 4), and emergent pericardiocentesis for tamponade (N = 1). Two patients died within days of presentation. Although pediatric cancers can present with severe initial findings, the clustered frequency and acuity of these recent initial presentations is striking.
TABLE 1

Clinical characteristics, presentation, and outcomes of children who presented in critical condition and were subsequently diagnosed with cancer

# Visits prior to diagnosis
PatientAge (years)SexSymptoms at presentationOnset of symptomsTele‐healthPMD/urgent careEDPresumed diagnosisTime from initial presentation to diagnosisOncologic diagnosisSARS‐CoV‐2 RT‐PCR assayNotable laboratory/radiologic findingsClinical courseSurvival status
14FFevers, emesis, hallucinations3 weeks211Viral syndrome2 weeksB‐cell ALLNegative × 2

WBC 1,000 /μL

Blasts 1.6%

Hgb 2.3 g/dL

Platelets 3,000 /μL

Lactate 13 mmol/L

Uric acid 19 mg/dL

Blood culture positive for Group G strep

Many clusters of bacterial organisms on BMA

Presented in shock. Cardiac arrest with multisystem organ failure. Brain herniation.

Hemodialysis delayed due to COVID‐19‐related staffing shortages.

Deceased (HD 5)
216MFevers, cough, emesis, diarrhea, dyspnea4.5 weeks012Asthma flare and acute otitis media4 weeksB‐cell ALLNegative × 3

WBC 1,000 /μL

Blasts 26%

Hgb 3 g/dL

Platelets 77 ,000 /μL

Lactate 15 mmol/L

Uric acid 11.5 mg/dL

Presented in respiratory distress. Cardiac arrest with multisystem organ failure. Small cerebral hemorrhages.Alive
317FAbdominal pain, cough, palpitations2.5 weeks401Gastritis2 weeksStage III DLBCLNegative × 1

Echocardiogram: large circumferential pericardial effusion with right atrial and ventricular collapse

CT chest: large anterior mediastinal mass

Presented in cardiac tamponade. 1.5 L malignant pericardial fluid emergently drained.Alive
410FShortness of breath, lethargy and cyanosis3 daysReported parental reluctance to present to care3 daysT‐cell lymphoblastic lymphomaNegative × 2

pH of 6.9

pCO2 100

Lactate of 9.2

CT chest: large anterior mediastinal mass

Presented in respiratory distress and obtunded. Emergently intubatedAlive
58MFevers, throat pain, pallor, bruising, vomiting, fatigue, and eye pain4 weeks020Tonsillitis4 weeksAMLNegative × 1

WBC 365,000 /μL

Blasts 89%

Hgb 6.1 g/dL

Platelets 28,000 /μL INR 1.7

Fibrinogen 191

Presented with altered mental status. Status epilepticus and emergent intubation. Intracranial hemorrhage and herniation.Deceased (HD 5)

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BMA, bone marrow aspirate; DLBCL, diffuse large b‐cell lymphoma; ED, emergency department; EMS, emergency medical services; HD, hospital day; Hgb, hemoglobin; PMD, primary medical doctor; WBC, white blood cell.

Clinical characteristics, presentation, and outcomes of children who presented in critical condition and were subsequently diagnosed with cancer WBC 1,000 /μL Blasts 1.6% Hgb 2.3 g/dL Platelets 3,000 /μL Lactate 13 mmol/L Uric acid 19 mg/dL Blood culture positive for Group G strep Many clusters of bacterial organisms on BMA Presented in shock. Cardiac arrest with multisystem organ failure. Brain herniation. Hemodialysis delayed due to COVID‐19‐related staffing shortages. WBC 1,000 /μL Blasts 26% Hgb 3 g/dL Platelets 77 ,000 /μL Lactate 15 mmol/L Uric acid 11.5 mg/dL Echocardiogram: large circumferential pericardial effusion with right atrial and ventricular collapse CT chest: large anterior mediastinal mass pH of 6.9 pCO2 100 Lactate of 9.2 CT chest: large anterior mediastinal mass WBC 365,000 /μL Blasts 89% Hgb 6.1 g/dL Platelets 28,000 /μL INR 1.7 Fibrinogen 191 AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BMA, bone marrow aspirate; DLBCL, diffuse large b‐cell lymphoma; ED, emergency department; EMS, emergency medical services; HD, hospital day; Hgb, hemoglobin; PMD, primary medical doctor; WBC, white blood cell. Coinciding with the rapid rise in regional COVID‐19 cases and initiation of stay‐at‐home orders, both institutions noted significant changes in the timing and severity of new patient presentations. The first COVID‐19 case in Pennsylvania was reported on March 6, 2020. Despite a five‐year historical mean of 2.96 days between new leukemia patients, CHOP did not see any patients with a new leukemia diagnosis for 35 days (March 2, 2020, to April 6, 2020). Comparatively, the longest gap from 2015 to 2019 was 18 days. Thus, it was notable when two patients subsequently diagnosed with acute lymphoblastic leukemia (ALL) presented on consecutive days to the pediatric intensive care unit (PICU) after having cardiac arrests at local hospitals in April. Similarly, LPCH noted an increase in the percentage of patients requiring prolonged PICU care at diagnosis. In April 2020, 75% of new leukemia/lymphoma diagnoses required PICU care, compared with a historic monthly average of 12% during 2018–2019 (previous maximum 40%). Pediatric cancers are relatively rare, and thus delays in diagnosis can occur. However, our experience suggests that additional factors specific to the ongoing COVID‐19 pandemic contributed to care delays and higher patient acuity. The family of one patient expressed reluctance to seek care due to fear of COVID‐19 exposure. The other four patient families had repeated contact with the healthcare system prior to ultimate diagnosis. This suggests that healthcare system factors may play a role, including decreased referrals to emergency departments or laboratories, and transition to alternative evaluation methods such as telemedicine. Diagnostic bias may also occur, since presenting signs of malignancy (fever, malaise, and respiratory symptoms) can initially be mistaken for symptoms of COVID‐19. Furthermore, endemic areas have reported that children are less likely to become critically ill from COVID‐19 disease as compared with adults, which may delay referral of children for emergency services or laboratory studies. Two patients had multiple telehealth visits prior to in‐person evaluations. Telemedicine utilization among primary and acute care providers is increasing during the pandemic. The limitations of telemedicine, including lack of ability to detect critical physical exam findings such as unstable vital signs, pallor, and hepatosplenomegaly, are underscored by these cases. For example, after two telehealth visits and one visual assessment outside the primary care provider's office, patient 1 re‐presented hours later to a local emergency department with overwhelming sepsis that progressed to cardiac arrest and brain death. Such an outcome is particularly difficult given the extremely favorable prognosis of childhood ALL. Indeed, the pediatric cancer diagnoses presented here are highly curable in North America with expected cure rates ranging from 67% to over 95% depending on diagnosis. These cases illustrate the indirect impact of this pandemic on morbidity in COVID‐19–negative patients for whom care delays can be fatal. We highlight the unintended consequences of a pandemic‐transformed healthcare system for a vulnerable pediatric population. More work is critical to quantify these consequences and to develop solutions that protect severely ill but treatable children, while also balancing public health and the needs of those infected during this COVID‐19 pandemic.

CONFLICTS OF INTEREST

The authors have no conflicts of interest/financial relationships relevant to this article to disclose.
  3 in total

1.  Virtually Perfect? Telemedicine for Covid-19.

Authors:  Judd E Hollander; Brendan G Carr
Journal:  N Engl J Med       Date:  2020-03-11       Impact factor: 91.245

2.  Delayed access or provision of care in Italy resulting from fear of COVID-19.

Authors:  Marzia Lazzerini; Egidio Barbi; Andrea Apicella; Federico Marchetti; Fabio Cardinale; Gianluca Trobia
Journal:  Lancet Child Adolesc Health       Date:  2020-04-09

3.  Childhood cancer and factors related to prolonged diagnostic intervals: a Danish population-based study.

Authors:  J M Ahrensberg; F Olesen; R P Hansen; H Schrøder; P Vedsted
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

  3 in total
  21 in total

1.  Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country.

Authors:  Mahmoud Hammad; Lobna Shalaby; Iman Sidhom; Nancy Sherief; Ibrahim Abdo; Sonia Soliman; Youssef Madeny; Reem Hassan; Shaimaa Elmeniawy; Nagwa Khamis; Iman Zaki; Tarek Mansour; Mohamed Gamal El-Ansary; Ahmed Al-Halfawy; Sherif Abouelnaga; Alaa Elhaddad
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2021-07-26

Review 2.  COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE).

Authors:  Jérémie Rouger-Gaudichon; Yves Bertrand; Nicolas Boissel; Benoit Brethon; Stéphane Ducassou; Virginie Gandemer; Carine Halfon-Domenech; Thierry Leblanc; Guy Leverger; Gérard Michel; Arnaud Petit; Anne-France Ray-Lunven; Pierre-Simon Rohrlich; Pascale Schneider; Nicolas Sirvent; Marion Strullu; André Baruchel
Journal:  Bull Cancer       Date:  2021-03-11       Impact factor: 1.276

3.  The impact of the COVID-19 pandemic on paediatric emergency service.

Authors:  İlknur Fidancı; Medine Ayşin Taşar; Bahar Akıntuğ; İzzet Fidancı; İsmail Bulut
Journal:  Int J Clin Pract       Date:  2021-06-05       Impact factor: 3.149

4.  Survival and Complications in Pediatric Patients With Cancer and COVID-19: A Meta-Analysis.

Authors:  Elisa Dorantes-Acosta; Diana Ávila-Montiel; Miguel Klünder-Klünder; Luis Juárez-Villegas; Horacio Márquez-González
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

5.  Pediatric cancer registration fluctuation in Greece due to COVID-19 pandemic and changes in health care delivery.

Authors:  Maria Kourti; George Markozannes; Panagiota Bouka; Evdoxia Bouka; Evangelia Ntzani; Eleni Th Petridou
Journal:  Pediatr Blood Cancer       Date:  2020-12-15       Impact factor: 3.838

6.  Delays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review.

Authors:  Rachel Riera; Ângela Maria Bagattini; Rafael Leite Pacheco; Daniela Vianna Pachito; Felipe Roitberg; Andre Ilbawi
Journal:  JCO Glob Oncol       Date:  2021-02

7.  A collateral effect of the COVID-19 pandemic: Delayed diagnosis in pediatric solid tumors.

Authors:  Stefano Chiaravalli; Andrea Ferrari; Giovanna Sironi; Giovanna Gattuso; Luca Bergamaschi; Nadia Puma; Elisabetta Schiavello; Veronica Biassoni; Marta Podda; Cristina Meazza; Filippo Spreafico; Michela Casanova; Monica Terenziani; Roberto Luksch; Maura Massimino
Journal:  Pediatr Blood Cancer       Date:  2020-08-06       Impact factor: 3.838

8.  Observed reduction in the diagnosis of acute lymphoblastic leukaemia in children during the COVID-19 pandemic.

Authors:  Kirsten Brunsvig Jarvis; Andreas Lind; Marissa LeBlanc; Ellen Ruud
Journal:  Acta Paediatr       Date:  2020-10-05       Impact factor: 4.056

9.  COVID-19 in pediatric cancer patients in a resource-limited setting: National data from Peru.

Authors:  Jacqueline Montoya; Cecilia Ugaz; Sandra Alarcon; Essy Maradiegue; Juan García; Rosdali Díaz; Arturo Zapata; Sharon Chávez; Roxana Morales; Katy Ordoñez; Eddy Hernandez; Rómulo Reaño; Cynthia Gutierrez; María Pía Vargas; Katherine Sanchez; Cinthya Valdiviezo; Iván Maza; Ninoska Rojas; Carla Moore; Esmeralda León; Liliana Vásquez
Journal:  Pediatr Blood Cancer       Date:  2020-07-22       Impact factor: 3.838

10.  Ethical responsibilities of European children's teams facing the resurgent COVID-19 pandemic.

Authors:  Anna Zanin; Enrico Furlan; Marek Migdal; Joe Brierley
Journal:  Eur J Pediatr       Date:  2021-07-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.